Offen W - Search Results

1

Overview of multiple testing methodology and recent development in clinical trials.

Wang D, Li Y, Wang X, Liu X, Fu B, Lin Y, Larsen L, Offen W. Wang D, et al. Among authors: offen w. Contemp Clin Trials. 2015 Nov;45(Pt A):13-20. doi: 10.1016/j.cct.2015.07.014. Epub 2015 Jul 22. Contemp Clin Trials. 2015. PMID: 26210511 Review.

2

Applications of general multistage gatekeeping and graphical multiple testing strategies in a clinical trial setting.

Li Y, Wang X, Wang D, Offen W. Li Y, et al. Among authors: offen w. Contemp Clin Trials. 2019 Jan;76:9-15. doi: 10.1016/j.cct.2018.10.004. Epub 2018 Oct 19. Contemp Clin Trials. 2019. PMID: 30343046

3

A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects.

Schnell PM, Tang Q, Offen WW, Carlin BP. Schnell PM, et al. Among authors: offen ww. Biometrics. 2016 Dec;72(4):1026-1036. doi: 10.1111/biom.12522. Epub 2016 May 9. Biometrics. 2016. PMID: 27159131 Free PMC article.

4

Challenge of multiple co-primary endpoints: a new approach.

Chuang-Stein C, Stryszak P, Dmitrienko A, Offen W. Chuang-Stein C, et al. Among authors: offen w. Stat Med. 2007 Mar 15;26(6):1181-92. doi: 10.1002/sim.2604. Stat Med. 2007. PMID: 16927251

5

Gatekeeping strategies for clinical trials that do not require all primary effects to be significant.

Dmitrienko A, Offen WW, Westfall PH. Dmitrienko A, et al. Among authors: offen ww. Stat Med. 2003 Aug 15;22(15):2387-400. doi: 10.1002/sim.1526. Stat Med. 2003. PMID: 12872297

6

Optimizing Graphical Procedures for Multiplicity Control in a Confirmatory Clinical Trial via Deep Learning.

Zhan T, Hartford A, Kang J, Offen W. Zhan T, et al. Among authors: offen w. Stat Biopharm Res. 2022;14(1):92-102. doi: 10.1080/19466315.2020.1799855. Epub 2020 Aug 24. Stat Biopharm Res. 2022. PMID: 35401935 Free PMC article.

7

A new classification approach for comparing two active treatments when there is no prior projection on which one is better.

Qu Y, Liu R, Dmitrienko A, Offen W. Qu Y, et al. Among authors: offen w. Stat Med. 2011 Dec 30;30(30):3488-95. doi: 10.1002/sim.4402. Epub 2011 Nov 15. Stat Med. 2011. PMID: 22086771

8

A simple stopping rule for declaring treatment ineffectiveness in clinical trials.

Enas GG, Offen WW. Enas GG, et al. Among authors: offen ww. J Biopharm Stat. 1993 Mar;3(1):13-22. doi: 10.1080/10543409308835046. J Biopharm Stat. 1993. PMID: 8485534

9

The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, Paul SM. Bodick NC, et al. Among authors: offen ww. Alzheimer Dis Assoc Disord. 1997;11 Suppl 4:S16-22. Alzheimer Dis Assoc Disord. 1997. PMID: 9339268 Clinical Trial.

10

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM. Bodick NC, et al. Among authors: offen ww. Arch Neurol. 1997 Apr;54(4):465-73. doi: 10.1001/archneur.1997.00550160091022. Arch Neurol. 1997. PMID: 9109749 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters